Leading the way in a new clinical trial

Exact Sciences has identified ECHO as the highest enroller nationally for the cancer cohort for their Ascend 2 clinical trial. This primary endpoint of this trial is hopefully identifying biomarkers for early detection of cancer. ECHO is recruiting healthy individuals with no history of cancer, as well as newly diagnosed cancer patients. We thank all participants for their altruism.

To learn more about this trial and many other clinical trials underway at ECHO, click here>